Amid shrinking research budgets and rising regulatory demands, clinical trials have become increasingly difficult to fund and execute. In response, the European Cardiovascular Research Institute (ECRI) was founded to bridge the gap between academic thought leaders and industry, enabling high-impact studies that advance cardiovascular care. We spoke with Director Ernest Spitzer below, as ECRI is named Europe’s Cardiology Research Organisation of the Year 2025 in the Global Excellence Awards.
Founded in 2012, the European Cardiovascular Research Institute is a non-profit organisation dedicated to advancing cardiovascular research through investigator-led clinical trials. Established in collaboration with specialised cardiovascular research organisation Cardialysis, ECRI’s mission is to defeat cardiovascular disease by conducting high-quality, independent, multicentre, and multinational studies that adhere to ICH and GCP standards.
At its core, ECRI’s vision is to serve as a non-profit hub that unites leading clinical researchers with industry partners to execute innovative trials within budget and timeline constraints. The organisation has dedicated itself to fostering global collaboration and leveraging a network of top cardiologists to ensure it successfully delivers impactful research that shapes clinical practice worldwide.
In a space oversaturated with commercially motivated organisations, ECRI distinguishes itself through its unwavering commitment to scientific integrity and patient-centred outcomes. Its non-profit model is not only a structural choice but also a philosophical stance that prioritises clinical relevance over marketability. By championing investigator-initiated studies, ECRI ensures that research questions arise from frontline clinical experience and reflect critical day-to-day questions at a given moment.
The organisation’s collaboration with Cardialysis further amplifies its distinctiveness, combining operational excellence with core lab capabilities to execute complex, multicentre trials across Europe. The result is a research environment where innovation thrives through rigorous methodology and global cooperation. This ethos is embodied in ECRI’s trial infrastructure, which supports the design and delivery of independent studies that challenge conventional standards and push the boundaries of cardiovascular care.
ECRI proudly offers a unique platform for executing ambitious, independent clinical trials designed to address critical concerns in the treatment of cardiac patients. The organisation’s pipeline of groundbreaking trials is driven by outstanding clinical leadership and highlights the organisation’s focus on innovative, evidence-based solutions that drive clinical advancements.
The organisation is advancing cardiology through three pivotal trials – IVUS-CHIP, OPTIMAL, and FAST III – each targeting critical gaps in percutaneous coronary intervention either for complex or intermediate coronary artery disease. With enrolment completed and results slated for presentation in 2026, these studies promise to reshape clinical guidelines, enhance patient outcomes, and optimise resource use in high-risk procedures.
Collectively, these ECRI-led trials could reduce PCI-related major adverse cardiovascular events by 15-30% across Europe, fostering imaging-integrated and physiology-driven care that prioritises precision over intuition.
“To advance this mission,” said Ernest, “ECRI is actively seeking private and public funding, including grants and donations, to support the execution of these impactful trials. By investing in our platform, funders can help drive transformative advancements in cardiovascular care, addressing unmet needs and shaping the future of clinical practice.”
Ultimately, ECRI aims to revolutionise cardiovascular clinical trials over the next five years by leveraging cutting-edge technologies and streamlined processes. The organisation will explore the use of artificial intelligence to enhance trial design and data analysis, using predictive models to optimise patient selection and endpoint detection, potentially reducing trial timelines by 15-20%.
To enhance consistency and accelerate regulatory approvals, ECRI is standardising protocols across multicentre trials like IVUS-CHIP and OPTIMAL, ensuring compliance with ICH and GCP guidelines. Automated data platforms are being designed to reduce manual errors and site burden, aiming for a 25% cut in data entry time. Real-time reporting tools will support faster, evidence-based decisions in studies such as FAST III. These digital innovations – anchored in AI, streamlined processes, and smart resource use – reflect ECRI’s drive to deliver cost-effective, high-impact research that shapes future cardiovascular care.
Looking ahead, ECRI announces the launch of the ZEPHYR trial, a groundbreaking study poised to transform post-myocardial infarction care. In a bold step towards defeating cardiovascular disease, ZEPHYR will investigate ziltivekimab – a promising anti-inflammatory drug from Novo Nordisk – against placebo in 332 patients with acute myocardial infarction. By targeting the IL-6 pathway, this trial aims to demonstrate how curbing chronic inflammation can stabilise and regress coronary plaques, potentially slashing residual risks that claim countless lives annually.
“As ECRI’s pipeline – including FAST III and OPTIMAL – advances toward 2026 milestones, this trial underscores our commitment to patient-centred breakthroughs,” Ernest shared. “Early engagements of academics in drug development promises not just insights, but real-world impact: fewer repeat events, better survival, and smarter healthcare strategies.
“Join us in this vital quest. For trial details, visit www.ecri-trials.com/studies/zephyr/. Together, we’re rewriting the future of cardiology – one plaque at a time.”
